Moderator: Igor Nikolic

Dr. Igor Nikolic is a Research Fellow at European University Institute, Italy. He specialises and writes in the areas of standard essential patents, innovation and technical standardisation, intellectual property and competition law. He published a book ‘Licensing Standard Essential Patents: FRAND and the Internet of Things’ (Hart Publishing 2021) examining the law, policy, and economics of SEP licensing. At EUI he gives lectures on patent licensing and 5G policy issues. Igor has given presentations at various international conferences and published in academic journals on different topics related to standardisation, FRAND commitment, SEP disputes, the appropriate level chain for licensing and licensing negotiations groups.

He obtained PhD at University College London, where he is also associated as a Senior Fellow at UCL’s Centre for Law, Economics & Society. He taught competition and IP law at UCL, King’s College and the University of Turin and worked as an external consultant for the World Bank. Igor is also a qualified attorney at law advising on competition, intellectual property and regulatory issues.

When AI Helps Generate Inventions, Who Is the Inventor?

By Andrei Iancu and Rama Elluru This commentary from the CSIS-SCSP Task Force on IP in the AI Era was originally published in the Special Competitive Studies Project’s Substack on February 15, 2024. With roots in the U.S. constitution, patent rights provide an exclusive property right in new inventions like drugs,
Read More

Standard Essential Patents and European Economic Security

By Kirti Gupta and Chris Borges On April 27, 2023, the European Commission published a draft proposal on standard essential patents (SEPs) seeking to address the perceived lack of transparency and predictability in the licensing of SEPs. The commission proposes the creation of a competence center within the European Union Intellectual
Read More

Proposed Federal Use of March-in Rights Would Weaken American Innovation

By Sujai Shivakumar and Thomas Howell   The Biden administration is considering exercising something called “march-in rights” as a policy prescription to curb drug prices. But as with any prescription, there is a need to weigh efficacy against the side-effects. In this case, there is evidence that the vast majority of
Read More